Vardenafil (Levitra/Staxyn) Cost vs. Alternatives in Class

What Vardenafil Costs Without Insurance

A single 20 mg generic vardenafil tablet ranges from about $2 to $12 at major US chain pharmacies, depending on the retailer and whether you use a discount coupon. That positions vardenafil in the middle of the PDE5 inhibitor pricing spectrum. Brand-name Levitra has been discontinued or is unavailable at most US pharmacies since Bayer's patent expired, but Staxyn (the orally disintegrating 10 mg formulation) still carries a premium of $30 to $50 per tablet where it remains stocked.

Pharmacy benefit managers negotiated sharply lower prices once generics entered the market in 2018. The result: cash-pay patients filling a prescription for eight tablets of generic vardenafil 20 mg can expect to spend $16 to $96 per month depending on where they fill it. Costco and independent pharmacies tend to cluster near the lower end, while CVS and Walgreens sit closer to the upper range before coupons are applied.

The FDA's Orange Book lists multiple AB-rated generic vardenafil products, confirming bioequivalence with brand Levitra. Patients switching from brand to generic should expect identical clinical performance at a fraction of the cost.

How Generic Sildenafil Compares on Price

Sildenafil is the cheapest option. Generic sildenafil 100 mg (the Viagra equivalent) regularly falls below $1 per tablet at discount pharmacies, and some digital health platforms offer it for $0.50 per dose in bulk quantities. For a patient using eight tablets per month, that translates to $4 to $24 total, roughly half to one-third what generic vardenafil costs at the same volume.

Sildenafil's cost advantage stems from the longest generic availability among PDE5 inhibitors (US patent expiration in 2012, with authorized generics from Teva launching in late 2017). Greater manufacturing competition has driven margins thin. A 2019 analysis in the Journal of Sexual Medicine documented that generic entry reduced mean sildenafil prices by over 80% within two years.

Clinically, sildenafil and vardenafil show similar efficacy. Both are short-acting PDE5 inhibitors with 4 to 6 hour windows. A randomized crossover trial by Rubio-Aurioles et al. (2006) comparing vardenafil 20 mg to sildenafil 100 mg found no statistically significant difference in the International Index of Erectile Function (IIEF) erectile-function domain score between the two drugs (PubMed). The practical takeaway: sildenafil delivers near-identical results for significantly less money.

Tadalafil Pricing and the Daily Dosing Factor

Generic tadalafil 20 mg on-demand costs $1 to $8 per tablet, comparable to vardenafil. But tadalafil offers something no other PDE5 inhibitor provides: an FDA-approved daily 2.5 mg or 5 mg regimen for both ED and benign prostatic hyperplasia (BPH). Daily tadalafil 5 mg runs $0.30 to $2 per tablet, meaning a 30-day supply can be as low as $9 at discount pharmacies.

The daily dosing model changes the cost equation entirely. A man paying $1.50 per day for daily tadalafil spends $45 per month for continuous erectile readiness and lower urinary tract symptom relief. That same $45 buys about four to six tablets of on-demand vardenafil. For patients who are sexually active more than twice per week, daily tadalafil often becomes the more economical and convenient choice.

Tadalafil's 36-hour half-life was established in the original FDA label review, which documented a 17.5-hour terminal half-life supporting the prolonged therapeutic window. Porst et al. (2003) established that PDE5 inhibitors, including vardenafil, produce reliable responses in difficult-to-treat populations like men with diabetes (PubMed). A separate head-to-head preference study published in European Urology found that 73% of men preferred tadalafil over sildenafil, primarily citing the longer duration of action rather than superior rigidity (PubMed).

Avanafil (Stendra): The Premium Option

Avanafil remains the most expensive PDE5 inhibitor. Brand Stendra 200 mg costs $40 to $70 per tablet without insurance, and no generic is available in the US as of early 2026. That price point puts it at 5 to 35 times the cost of generic sildenafil per dose.

What does that premium buy? Speed. Avanafil's onset can be as fast as 15 minutes in some patients, versus 30 to 60 minutes for vardenafil and sildenafil. A phase III trial by Goldstein et al. (2012) published in the Journal of Sexual Medicine demonstrated that avanafil 200 mg enabled successful intercourse as early as 15 minutes post-dose in 64.3% of attempts, compared to 47.5% for placebo (PubMed). Avanafil also shows greater selectivity for PDE5 over PDE6, which may translate to fewer visual disturbances.

For most patients, the marginal speed advantage does not justify a 10x cost difference. Avanafil makes the most sense for men who need the fastest possible onset, experience visual side effects with other PDE5 inhibitors, or have insurance that covers brand Stendra with a manageable copay.

Insurance Coverage Patterns Across All Four Drugs

Most commercial insurance plans and Medicare Part D formularies cover at least one generic PDE5 inhibitor, typically sildenafil or tadalafil. Quantity limits are standard. Six to twelve tablets per month is the usual cap, and prior authorization may be required for vardenafil if sildenafil or tadalafil is on the preferred tier.

Step therapy is common. Insurers frequently require a trial and documented failure of generic sildenafil before covering generic vardenafil or tadalafil. The American Urological Association's 2018 ED guideline recommends offering all PDE5 inhibitors as first-line therapy without mandating a specific agent, but payer policies rarely mirror clinical guidelines.

VA and DoD formularies typically cover generic sildenafil and generic tadalafil. Vardenafil may require a non-formulary request. Stendra is almost universally non-formulary across government and commercial plans.

For patients paying cash, manufacturer coupons and pharmacy discount cards (GoodRx, RxSaver, Amazon Pharmacy) can reduce generic vardenafil prices to $2 to $4 per tablet. These programs fluctuate month to month, so checking multiple platforms before filling is worth the effort.

Mechanism of Action: How Vardenafil Works

All four FDA-approved ED medications share the same basic mechanism. They are selective inhibitors of phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum smooth muscle. Sexual stimulation triggers nitric oxide release, which activates guanylate cyclase to produce cGMP. The cGMP relaxes smooth muscle, increases arterial inflow, and compresses subtunical venules to produce and maintain an erection. PDE5 inhibitors block the breakdown of cGMP, amplifying and prolonging this natural response (PubMed review).

Vardenafil is the most potent PDE5 inhibitor by IC50. Its in vitro IC50 for PDE5 is 0.7 nM, compared to 3.5 nM for sildenafil and 6.7 nM for tadalafil. This does not mean vardenafil is "stronger" at clinical doses. The approved doses are calibrated so that each drug produces roughly equivalent PDE5 inhibition at standard dosing (vardenafil 20 mg, sildenafil 100 mg, tadalafil 20 mg). The practical result is similar efficacy across agents, as confirmed in a 2013 network meta-analysis by Yuan et al. published in European Urology that found no significant differences in IIEF score improvements among the three older PDE5 inhibitors (PubMed).

Where vardenafil's pharmacology does differ meaningfully is PDE selectivity. Vardenafil has moderate inhibition of PDE11 (less than tadalafil) and minimal PDE6 inhibition (less visual disturbance risk than sildenafil). These selectivity differences explain some of the side-effect variations between agents.

Side-Effect Profiles and Their Cost Implications

Side effects carry hidden costs. A patient who develops flushing or nasal congestion severe enough to avoid the drug has wasted money on unused tablets. Headache is the most common adverse event for all PDE5 inhibitors, reported at roughly similar rates: 15% for sildenafil 100 mg, 15% for vardenafil 20 mg, 14% for tadalafil 20 mg, and 10% for avanafil 200 mg (PubMed).

The clinically relevant differentiators are these. Sildenafil causes blue-tinted vision (cyanopsia) in 3 to 11% of users due to PDE6 cross-reactivity; vardenafil causes this in under 2%. Tadalafil produces back pain and myalgia in 4 to 6% of users (unique to its class due to PDE11 inhibition); vardenafil and sildenafil rarely cause this. Vardenafil carries a QTc prolongation warning and should be avoided in patients taking Class IA or III antiarrhythmics, per the FDA prescribing information.

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and a contributor to the AUA ED guideline, has stated: "PDE5 inhibitor selection should be individualized based on patient preference, dosing flexibility, onset and duration requirements, and comorbidity profile rather than assumed efficacy differences."

Vardenafil for Diabetic ED: The Porst Trial

Diabetes is the single most common medical cause of ED, affecting 35 to 75% of men with the disease. PDE5 inhibitors work less reliably in this population because chronic hyperglycemia damages endothelial nitric oxide synthase, reducing the NO substrate that PDE5 inhibitors depend on.

Porst et al. (2003) conducted a randomized, double-blind, placebo-controlled trial of vardenafil in 452 men with type 1 or type 2 diabetes and ED. Vardenafil 20 mg improved the IIEF erectile-function domain score by a mean of 6.6 points versus 1.4 for placebo (P<0.001). The successful intercourse rate was 49% with vardenafil 10 mg and 54% with vardenafil 20 mg, compared to 23% with placebo (PubMed).

These numbers matter for the cost discussion. A 54% per-attempt success rate means roughly half of purchased tablets contribute to a successful sexual encounter. At $6 per tablet, the effective cost per successful act is approximately $11 to $12. With generic sildenafil at $1.50 per tablet and a similar 50 to 60% success rate in diabetic men (established in Goldstein et al., Diabetes Care 2003 (PubMed)), the effective cost per successful act drops to roughly $2.50 to $3.

The Cost-per-Successful-Encounter Framework

Comparing sticker prices alone misses the point. The metric that matters is cost per successful sexual encounter, which accounts for efficacy differences, tolerability-driven waste, and dosing flexibility.

The American Association of Clinical Endocrinology (AACE) recommends PDE5 inhibitors as first-line pharmacotherapy for ED in men with metabolic disease (AACE Guidelines). Their guidance emphasizes trial-and-error across agents, acknowledging that individual response varies by 20 to 30% between drugs for reasons that are poorly understood.

A practical way to minimize cost: start with generic sildenafil 100 mg (which can be split into 50 mg halves for $0.25 to $1.50 per dose). If sildenafil fails after four to six attempts at full dose, switch to generic tadalafil 20 mg or daily tadalafil 5 mg. Reserve generic vardenafil for patients who tolerate sildenafil poorly (visual symptoms, severe flushing) or who prefer its faster onset compared to tadalafil. Reserve avanafil for patients who need the fastest possible onset and can afford the cost premium.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that PDE5 inhibitors may be combined with testosterone replacement in hypogonadal men with ED to improve response rates, as testosterone restores the NO/cGMP substrate that PDE5 inhibitors require (PubMed).

When Vardenafil Is the Best Value

Vardenafil occupies a specific clinical niche that justifies its mid-range price. The ideal candidate is a man who experiences visual side effects on sildenafil, needs on-demand dosing rather than daily therapy, and either cannot tolerate tadalafil's myalgia or does not want a 36-hour drug window.

Staxyn (the orally disintegrating tablet) adds another niche: patients who have difficulty swallowing pills or who prefer a discreet, no-water-needed format. The ODT formulation has a slightly different pharmacokinetic profile with a faster Tmax than the standard tablet, though the clinical significance of this difference is modest. At $30 to $50 per tablet, Staxyn is hard to justify on cost grounds alone.

For the general ED population without specific tolerability concerns, generic sildenafil at $0.50 to $3 per tablet remains the rational first choice. As Dr. Irwin Goldstein, Director of Sexual Medicine at Alvarado Hospital, has noted: "Generic sildenafil has become so inexpensive that cost should no longer be a barrier to treating erectile dysfunction in the United States."

Patients filling vardenafil prescriptions should request the 20 mg tablet regardless of prescribed dose, then split tablets if 10 mg is sufficient. This simple step cuts the per-dose cost in half. Tablet-splitting is explicitly supported by the drug's scored tablet design and is consistent with AUA guideline recommendations for cost-conscious PDE5 inhibitor prescribing.